JP2017532285A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532285A5
JP2017532285A5 JP2016549442A JP2016549442A JP2017532285A5 JP 2017532285 A5 JP2017532285 A5 JP 2017532285A5 JP 2016549442 A JP2016549442 A JP 2016549442A JP 2016549442 A JP2016549442 A JP 2016549442A JP 2017532285 A5 JP2017532285 A5 JP 2017532285A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bcl
nutrin
inhibiting
mdm2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549442A
Other languages
English (en)
Japanese (ja)
Other versions
JP6688224B2 (ja
JP2017532285A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/013387 external-priority patent/WO2015116740A1/en
Publication of JP2017532285A publication Critical patent/JP2017532285A/ja
Publication of JP2017532285A5 publication Critical patent/JP2017532285A5/ja
Application granted granted Critical
Publication of JP6688224B2 publication Critical patent/JP6688224B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549442A 2014-01-28 2015-01-28 Ｍｄｍ２を阻害する手段の投与による関節における変形性関節症の処置 Expired - Fee Related JP6688224B2 (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201461932711P 2014-01-28 2014-01-28
US201461932704P 2014-01-28 2014-01-28
US61/932,711 2014-01-28
US61/932,704 2014-01-28
US201461979911P 2014-04-15 2014-04-15
US61/979,911 2014-04-15
US201462002709P 2014-05-23 2014-05-23
US62/002,709 2014-05-23
US201462042708P 2014-08-27 2014-08-27
US62/042,708 2014-08-27
US201462044664P 2014-09-02 2014-09-02
US62/044,664 2014-09-02
US201462057820P 2014-09-30 2014-09-30
US201462057825P 2014-09-30 2014-09-30
US201462057828P 2014-09-30 2014-09-30
US62/057,828 2014-09-30
US62/057,825 2014-09-30
US62/057,820 2014-09-30
US201462061629P 2014-10-08 2014-10-08
US201462061627P 2014-10-08 2014-10-08
US62/061,629 2014-10-08
US62/061,627 2014-10-08
PCT/US2015/013387 WO2015116740A1 (en) 2014-01-28 2015-01-28 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019083555A Division JP2019142933A (ja) 2014-01-28 2019-04-25 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬
JP2020038529A Division JP2020105213A (ja) 2014-01-28 2020-03-06 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬

Publications (3)

Publication Number Publication Date
JP2017532285A JP2017532285A (ja) 2017-11-02
JP2017532285A5 true JP2017532285A5 (enExample) 2018-03-08
JP6688224B2 JP6688224B2 (ja) 2020-04-28

Family

ID=53757701

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016549442A Expired - Fee Related JP6688224B2 (ja) 2014-01-28 2015-01-28 Ｍｄｍ２を阻害する手段の投与による関節における変形性関節症の処置
JP2019083555A Pending JP2019142933A (ja) 2014-01-28 2019-04-25 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬
JP2020038529A Withdrawn JP2020105213A (ja) 2014-01-28 2020-03-06 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬
JP2021081356A Pending JP2021138712A (ja) 2014-01-28 2021-05-13 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物
JP2023110762A Pending JP2023126918A (ja) 2014-01-28 2023-07-05 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019083555A Pending JP2019142933A (ja) 2014-01-28 2019-04-25 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬
JP2020038529A Withdrawn JP2020105213A (ja) 2014-01-28 2020-03-06 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬
JP2021081356A Pending JP2021138712A (ja) 2014-01-28 2021-05-13 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物
JP2023110762A Pending JP2023126918A (ja) 2014-01-28 2023-07-05 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物

Country Status (14)

Country Link
US (19) US9993472B2 (enExample)
EP (2) EP3099380B1 (enExample)
JP (5) JP6688224B2 (enExample)
KR (1) KR102496146B1 (enExample)
CN (3) CN106163557B (enExample)
AU (4) AU2015211021B2 (enExample)
BR (1) BR112016017564A8 (enExample)
CA (2) CA3100140C (enExample)
IL (3) IL286427B2 (enExample)
MX (2) MX2016009753A (enExample)
NZ (1) NZ723035A (enExample)
RU (1) RU2716256C2 (enExample)
SG (2) SG10201805670QA (enExample)
WO (1) WO2015116740A1 (enExample)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102037119B (zh) 2008-05-23 2015-06-24 Siwa有限公司 促进再生的方法、组合物及设备
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
CN106456699B (zh) 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
WO2015171723A1 (en) * 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
CA2955972A1 (en) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
JP2018508569A (ja) * 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US20180345047A1 (en) * 2015-02-26 2018-12-06 Yeda Research And Development Co. Ltd. Method of promoting hair growth
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017002120A1 (en) * 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
US11111259B2 (en) 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
IL283726B2 (en) 2016-02-19 2025-05-01 Siwa Corp A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer
SG10201913290QA (en) * 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US20190054097A1 (en) * 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
WO2017223107A1 (en) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
CN108473487B (zh) 2016-12-13 2021-08-03 普林斯顿药物研发公司 一种蛋白激酶抑制剂
US20240044046A1 (en) * 2017-01-03 2024-02-08 Bioatla, Inc. Protein therapeutics for treatment of senescent cells
JP7790686B2 (ja) 2017-01-03 2025-12-23 バイオアトラ インコーポレイテッド 老化細胞の処置のためのタンパク質療法
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
JP2020511674A (ja) 2017-03-09 2020-04-16 クリラ バイオテック ベー．フェー． 細胞老化バイオマーカー
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
TWI651087B (zh) * 2017-04-21 2019-02-21 Chang Gung University 類泛素化抑制劑於預防或治療骨質疏鬆症的用途
EP3619540A1 (en) * 2017-05-04 2020-03-11 Siwa Corporation Diagnostic advanced glycation end-product antibodies
AU2018202878A1 (en) * 2017-05-16 2018-12-06 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
GB201708456D0 (en) * 2017-05-26 2017-07-12 Medical Res Council Senolytic compounds
US20180344865A1 (en) * 2017-05-31 2018-12-06 Palo Alto Investors Methods of Increasing Fertility in a Female Subject
SG11201911909UA (en) * 2017-06-16 2020-01-30 Unity Biotechnology Inc Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
US20210154184A1 (en) 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
CN111372598A (zh) * 2017-08-11 2020-07-03 联合生物科技公司 使用消除衰老细胞的药剂治疗诸如黄斑变性,青光眼,和糖尿病性视网膜病变等眼科状况
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
JP7370599B2 (ja) * 2017-10-06 2023-10-30 バック・インスティテュート・フォー・リサーチ・オン・エイジング 老化細胞のためのバイオマーカー
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
AU2018357829B2 (en) 2017-12-30 2019-09-26 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
WO2019133904A1 (en) * 2017-12-30 2019-07-04 Unity Biotechnology, Inc. Inhibitors of hsp90, pi3-kinase, proteasome, hdac, and p97 pathways for selective removal of senescent cells in the treatment of age related conditions
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
CN112136048A (zh) * 2018-02-21 2020-12-25 艾迪菲斯健康有限公司 测量全身性慢性炎性衰老的方法
WO2019183282A1 (en) * 2018-03-21 2019-09-26 Mayo Foundation For Medical Education And Research Senolytic agents for the treatment of tauopathies
WO2019198091A1 (en) 2018-04-12 2019-10-17 Yeda Research And Development Co. Ltd. Blood based treatment
WO2019213151A1 (en) 2018-04-30 2019-11-07 Unity Biotechnology Phosphonamidates that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
JP7402225B2 (ja) 2018-05-11 2023-12-20 ロード アイランド ホスピタル ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法
WO2019221755A1 (en) 2018-05-18 2019-11-21 Bioventures, Llc Piperlongumine analogues and uses thereof
US11435364B2 (en) * 2018-05-24 2022-09-06 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
US11003537B2 (en) 2018-05-29 2021-05-11 Micron Technology, Inc. Determining validity of data read from memory by a controller
US11925640B2 (en) 2018-06-22 2024-03-12 Mayo Foundation For Medical Education And Research Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality
MX2021000395A (es) 2018-07-11 2021-05-12 Rubedo Life Sciences Inc Composiciones senolíticas y usos de las mismas.
EP3824291A1 (en) * 2018-07-20 2021-05-26 Roche Diagnostics GmbH Prediction of preeclampsia based on igfbp-7
CN109406764B (zh) * 2018-09-13 2022-02-01 中国辐射防护研究院 腹腔放疗后药物体内过程评价动物模型的建立与评价方法
TWI824010B (zh) * 2018-09-18 2023-12-01 加拿大商聖諾康生命科學公司 治療血癌之組合療法
US20210361774A1 (en) 2018-10-16 2021-11-25 Dana-Farber Cancer Institute, Inc. Degraders of wild-type and mutant forms of lrrk2
EP3697412B1 (en) * 2018-12-14 2026-02-25 Ascentage Pharma (Suzhou) Co., Ltd. A compound for treating osteoarthritis
US20210379068A1 (en) * 2018-12-20 2021-12-09 Mayo Foundation For Medical Education And Research Methods and materials for treating neuropsychiatric disorders
WO2020150394A1 (en) * 2019-01-15 2020-07-23 The Johns Hopkins University Regulation of a foreign body response
FR3091864B1 (fr) 2019-01-20 2022-07-29 Waterdiam France Eau électrolysée, procédé d’obtention et utilisations d’une telle eau pour le traitement de désordres liés à la sénescence cellulaire
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
CN111494366A (zh) * 2019-01-31 2020-08-07 洛阳尚德药缘科技有限公司 二甲基氨基含笑内酯在制备抗衰老药物上的应用
CN110161226A (zh) * 2019-02-27 2019-08-23 杭州晟康细胞生物科技有限公司 一种检测衰老细胞用的抗体、试剂盒及检测方法
EP3705109A1 (en) 2019-03-05 2020-09-09 Greenaltech, S.L. Carotenoids in the treatment of senescence-related diseases
EP4365590B1 (en) 2019-03-20 2025-09-24 Juntendo Educational Foundation Agent targeting double-membrane organelle dna
ES3055186T3 (en) 2019-04-04 2026-02-10 Dana Farber Cancer Inst Inc Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
CN114126599A (zh) * 2019-06-10 2022-03-01 巴克老龄化研究所 改变衰老相关分泌表型的方法和组合物
WO2020257173A1 (en) * 2019-06-17 2020-12-24 Unity Biotechnology, Inc. Method of treating the osteoarthritic joint
CN111407884B (zh) * 2019-06-24 2021-12-07 浙江大学 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途
CN110934873B (zh) * 2019-08-22 2022-10-28 中国科学院上海营养与健康研究所 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
CN112707900B (zh) * 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021113152A1 (en) * 2019-12-02 2021-06-10 Viome, Inc. Detection and elimination of aberrant cells
CA3163593A1 (en) 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
AU2021283886A1 (en) * 2020-06-02 2023-01-19 Buck Institute For Research On Aging Dihomo-gamma linolenic acid (DGLA) is a novel senolytic
EP4168436A4 (en) * 2020-06-17 2024-07-31 Mayo Foundation for Medical Education and Research EVALUATION AND TREATMENT OF BIOLOGICAL AGING
CN111973578A (zh) * 2020-08-03 2020-11-24 天津医科大学 C188-9、Venetoclax、Bumetanide在纤维化疾病药物中的应用
KR20220056730A (ko) * 2020-10-28 2022-05-06 의료법인 성광의료재단 Abt263을 유효성분으로 포함하는 디스크 질환 예방 및 치료용 조성물
CN112294962B (zh) * 2020-11-13 2023-06-06 上海长海医院 Bcl-2及bcl-xl抑制剂在瘢痕治疗中的应用
CN112891358B (zh) * 2020-11-19 2023-05-12 苏州正永生物医药有限公司 Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物
JPWO2022138700A1 (enExample) * 2020-12-23 2022-06-30
WO2022165172A1 (en) * 2021-01-29 2022-08-04 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing amyloid precursor protein (app)
US20220354805A1 (en) * 2021-04-30 2022-11-10 Hemix Biotech Limited Cannabidiol (CBD) as Chemical for Treating Aging-related Degenerative Diseases and Promoting Health Aging
KR102625248B1 (ko) * 2021-05-04 2024-01-16 주식회사 퓨전바이오텍 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물
CN113341126A (zh) * 2021-05-07 2021-09-03 中国科学院动物研究所 一种评价或辅助评价海马组织衰老的标志物
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
CN113509555B (zh) * 2021-07-19 2022-05-03 中国药科大学 Akt2抑制剂在制备非酒精性脂肪肝病治疗药物中的应用
CA3229602A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
US20250177115A1 (en) * 2021-08-20 2025-06-05 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
CN113694071B (zh) * 2021-08-31 2025-08-15 上海交通大学医学院附属瑞金医院 清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
CN118475356A (zh) * 2021-09-13 2024-08-09 鲁贝多生命科学公司 糖衍生物的药物偶联物及其作为衰老细胞裂解剂的用途
US11897915B2 (en) 2021-09-13 2024-02-13 Rubedo Life Sciences, Inc. Sugar derivatives and uses thereof to prepare novel senolytic agents
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
WO2023096448A1 (ko) * 2021-11-29 2023-06-01 에스케이케미칼 주식회사 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도
WO2023146979A1 (en) * 2022-01-27 2023-08-03 The Board Of Trustees Of The Leland Stanford Junior University A single cell mass cytometry platform to map the effects of candidate agents on cartilage
KR102879114B1 (ko) * 2022-03-29 2025-11-05 주식회사 퓨전바이오텍 당 결합된 이미다졸린 유도체 및 이의 용도
WO2023191513A1 (ko) * 2022-03-29 2023-10-05 주식회사 퓨전바이오텍 당 결합된 이미다졸린 유도체 및 이의 용도
US20250332198A1 (en) * 2022-06-01 2025-10-30 Sens Research Foundation Targeted elimination of senescent cells by gamma-delta t cells
KR20250029225A (ko) 2022-07-01 2025-03-04 제이제이알앤디 엘엘씨 화학 요법 유발된 탈모증의 예방 및 치료 방법
WO2024039646A1 (en) * 2022-08-15 2024-02-22 Mayo Foundation For Medical Education And Research Methods and materials for using and assessing anti-senescence treatments within mammals
CN118063438A (zh) * 2022-11-14 2024-05-24 北京华益健康药物研究中心 Mdm2/mdmx双靶点抑制剂化合物、前药、药物组合物及其制备方法和应用
EP4649499A1 (en) * 2023-01-12 2025-11-19 Koninklijke Philips N.V. Model-guided imaging for mechanical ventilation
WO2024229271A1 (en) * 2023-05-03 2024-11-07 Memorial Sloan-Kettering Cancer Center Nanoparticle-based theranostic platform for diagnosis and treatment of senescence-related pathologies
WO2025054580A1 (en) * 2023-09-08 2025-03-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction
IL327816A (en) * 2023-11-03 2026-06-01 Taiwan Liposome Co Ltd Liposomal composition of intra-articular corticosteroid for pain control
IL328585A (en) * 2023-11-27 2026-07-01 Rubedo Life Sciences Inc Phosphorus-containing BCL inhibitors and senolytic compounds and uses thereof
KR20260001876A (ko) 2024-06-28 2026-01-06 바이오스펙트럼 주식회사 발효 동백종자 추출물을 포함하는 일주기 리듬 장애 또는 세포 노화 예방 또는 개선용 조성물
WO2026050667A1 (en) * 2024-08-29 2026-03-05 Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Compositions and methods for treating infections in cystic fibrosis patients with senolytic agents
JP7876955B1 (ja) * 2025-04-08 2026-06-22 株式会社ファンケル 老化免疫細胞率の推定方法

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021342A (en) 1910-04-20 1912-03-26 James D Swindell Furnace.
US1025861A (en) 1911-12-12 1912-05-07 John Martin Case Train-order holder.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5700638A (en) 1993-08-26 1997-12-23 Washington University Cell death regulator
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
IL129951A0 (en) 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
ES2356342T3 (es) 1998-01-05 2011-04-07 The University Of Washington Mejora de transporte utilizando agentes de alteración de membrana.
US20020197602A1 (en) 1998-04-15 2002-12-26 Glenna C. Burmer Nucleic acid sequences and proteins associated with aging
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
US20020068704A1 (en) 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
GB9910119D0 (en) 1999-04-30 1999-06-30 Novartis Ag Organic compounds
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US6656461B1 (en) 2000-02-29 2003-12-02 The Trustees Of Columbia University In The City Of New York Therapeutic treatment of chronic obstructive pulmonary disease
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2003018057A1 (en) 2001-07-26 2003-03-06 Santen Pharmaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect
WO2003028443A1 (en) 2001-09-28 2003-04-10 The Walter And Eliza Hall Institute Of Medical Research Screening methods for agents that modulate degenerative disorders associated with bcl-2-and bim
US20030086916A1 (en) 2001-10-12 2003-05-08 Goligorsky Michael S. Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
JP4361798B2 (ja) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
WO2003104482A1 (en) 2002-06-05 2003-12-18 Metabolic Engineering Laboratories Co., Ltd. Signals and molecular species involved in senescence
FI117094B (fi) * 2003-01-15 2006-06-15 Fractivator Oy Menetelmä orgaanisen jätteen hajottamiseksi
ES2569780T3 (es) 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
KR20060111898A (ko) * 2003-08-29 2006-10-30 교와 가부시키가이샤 지질-풍부-플라크의 안정화 방법 및 파열 예방방법
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
GB0411166D0 (en) 2004-05-19 2004-06-23 Bionovate Ltd Treatment for asthma and arthritis
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
GB0418388D0 (en) 2004-08-18 2004-09-22 Univ Newcastle Cell therapy
WO2006039704A2 (en) 2004-09-30 2006-04-13 Janssen Pharmaceutica, N.V. Pharmaceutical composition and method for treating a joint capsule arthropathy
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
EP1888543B1 (en) 2005-05-24 2012-08-01 Abbott Laboratories Apoptosis promoters
CN101316823B (zh) 2005-12-01 2013-05-22 霍夫曼-拉罗奇有限公司 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物
US8877229B2 (en) 2005-12-02 2014-11-04 Eyetech Inc. Controlled release microparticles
BRPI0710477A2 (pt) 2006-01-18 2011-08-16 Hoffmann La Roche cis-4, 5- biarila - 2- imidazolinas heterocìclicas como inibidores da mdm2
US8470785B2 (en) 2006-07-28 2013-06-25 St. Jude Children's Research Hospital Method for treating ocular cancer
WO2008014216A1 (en) * 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
US20100292200A1 (en) 2006-08-11 2010-11-18 The Walter And Eliza Hall Institute Of Medical Research Methods for Modulating Apoptosis in Platelets
CA2661354C (en) * 2006-08-30 2012-12-18 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
CN101641338A (zh) * 2006-09-11 2010-02-03 柯瑞斯公司 作为抗增殖制剂的多功能小分子
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
AU2007319209B2 (en) 2006-11-15 2012-04-19 Genentech, Inc. Arylsulfonamide compounds
US20100087436A1 (en) 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20080125487A1 (en) * 2006-11-17 2008-05-29 Tapas Das Elongase gene and uses thereof
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008106507A2 (en) * 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
WO2008113131A1 (en) 2007-03-20 2008-09-25 The Walter And Eliza Hall Institute Of Medical Research Method of screening
BRPI0810082A2 (pt) * 2007-03-29 2014-10-21 Novartis Ag 3-imidazolil-indóis para o tratamento de doenças proliferativas
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
US20110028437A1 (en) 2007-07-31 2011-02-03 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
US20100310504A1 (en) 2007-09-26 2010-12-09 Lowe Scott W Methods for treating fibrosis by modulating cellular senescence
EP2193127A4 (en) 2007-09-27 2011-09-14 Inst Medical W & E Hall BENZOTHIAZOLE COMPOUNDS
US9115061B2 (en) 2007-10-19 2015-08-25 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
WO2009105234A2 (en) 2008-02-19 2009-08-27 Combinatorx, Incorporated Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
US8470607B2 (en) 2008-03-20 2013-06-25 Morphotek, Inc. Inhibition of angiogenesis
CA2716628A1 (en) 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
US7782903B2 (en) 2008-05-14 2010-08-24 Newport Media, Inc. Hardware accelerated protocol stack
CN102037119B (zh) 2008-05-23 2015-06-24 Siwa有限公司 促进再生的方法、组合物及设备
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
EP2349233A4 (en) 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH MACULAR DEGENERATION
CN101507729B (zh) * 2008-10-23 2010-12-22 昆明诺唯金参生物工程有限责任公司 人参皂苷Compound K在制备防治动脉粥样硬化的药物中的应用
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
KR101685718B1 (ko) 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
EP2376085B1 (en) 2008-12-19 2014-02-26 Genentech, Inc. Compounds and methods of use
US20130302283A1 (en) 2012-05-14 2013-11-14 Advanced Technologies And Regenerative Medicine, Llc hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS
NZ616828A (en) 2009-01-19 2015-03-27 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20120046333A1 (en) * 2009-04-09 2012-02-23 Oncothyreon Incorporated Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010148447A1 (en) 2009-06-23 2010-12-29 Centenary Institute Of Cancer Medicine And Cell Biology A novel regulator of cellular senescence
KR20120085781A (ko) * 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
RU2576512C2 (ru) 2009-11-04 2016-03-10 Хэлс Ресеч Инк. Способ и композиции для подавления старения
TW201127384A (en) 2009-11-18 2011-08-16 Nerviano Medical Sciences Srl Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
CA2786777A1 (en) 2010-01-07 2011-07-14 Akron Molecules Gmbh Obesity small molecules
US20130149314A1 (en) 2010-02-09 2013-06-13 Jörn Bullerdiek p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth
US10159669B2 (en) 2010-03-02 2018-12-25 Ian H. Chan Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use
AU2011229862B2 (en) 2010-03-25 2014-07-24 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8675704B2 (en) 2010-04-29 2014-03-18 Sri International Single ridge N-P-N diode laser
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
US20130287763A1 (en) 2010-07-28 2013-10-31 Merck Sharp & Dohme Corp. Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US9102668B2 (en) 2010-09-08 2015-08-11 Glaxo Group Limited Polymorphs and salts
US20130225603A1 (en) 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
WO2012045018A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2966040A1 (fr) 2010-10-19 2012-04-20 Brigitte Gourlaouen Composition amincissante et/ou de prevention des processus inflammatoires
KR20180059560A (ko) 2010-10-29 2018-06-04 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US8741905B2 (en) 2010-11-05 2014-06-03 The Broad Institute, Inc. Compounds and methods for treating autoimmune diseases
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
PE20140408A1 (es) 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
KR101762724B1 (ko) 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
EP2667874A4 (en) 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
US9737532B2 (en) * 2011-01-31 2017-08-22 Tokyo University Of Science Foundation Method of treating ischemia/reperfusion injury
KR20130131461A (ko) 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
KR101426689B1 (ko) * 2011-04-19 2014-08-08 가톨릭대학교 산학협력단 Ｎｕｔｌｉｎ­３ａ 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
TWI497333B (zh) 2011-06-14 2015-08-21 Giant Mfg Co Ltd 自行車適配產生方法、自行車適配系統與電腦程式產品
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
US9140213B2 (en) * 2011-12-06 2015-09-22 United Technologies Corporation Leaf spring damper for a turbine engine fuel delivery system
CA2859385A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
US8747112B2 (en) 2011-12-30 2014-06-10 Nobel Biocare Services Ag Abutment position locator
CA2861521A1 (en) 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No.2) Limited Novel use
WO2013155077A1 (en) 2012-04-09 2013-10-17 Board Of Regents,The University Of Texas System Response markers for src inhibitor therapies
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
KR101725571B1 (ko) * 2012-06-13 2017-04-11 가톨릭대학교 산학협력단 Ｍｄｍ２ 억제제를 유효성분으로 포함하는 노화 억제용 조성물
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2879332C (en) 2012-08-13 2022-08-30 Abbvie Inc. 1,2,3,4- tetrahydroisoquinoline-8-carboxamide compounds and their use as apoptosis-inducing agents
US9104666B2 (en) 2012-09-04 2015-08-11 Oracle International Corporation Controlling access to a large number of electronic resources
MX349551B (es) 2012-10-10 2017-08-02 Hoffmann La Roche Proceso para preparar compuestos tienopirimidinas.
EP2945940B1 (en) 2013-01-16 2020-07-15 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
KR102310786B1 (ko) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
US10799473B2 (en) 2013-03-04 2020-10-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20230148263A (ko) * 2013-03-15 2023-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
US20140272947A1 (en) 2013-03-15 2014-09-18 Fox Chase Cancer Center Methods and compositions for screening modulators of oncogene-induced senescence
BR112015026702A2 (pt) 2013-04-21 2018-02-06 Yeda Res And Developmente Co Ltd métodos de extermínio de células senescentes
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
WO2014205244A1 (en) 2013-06-19 2014-12-24 Demaria Marco Methods for enhancing effectiveness of medical therapies
WO2015017803A1 (en) 2013-08-02 2015-02-05 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
WO2015051252A1 (en) 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
US9909125B2 (en) 2013-11-01 2018-03-06 Everon Biosciences, Inc. Molecular targets for selective eradication of senescent cells
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
US9993472B2 (en) * 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190000846A1 (en) 2014-01-28 2019-01-03 Mayo Foundation For Medical Education And Research Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
CN106456699B (zh) * 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
GB201409519D0 (en) 2014-05-29 2014-07-16 Univ Leicester Senescent cell biomarkers
JP2018508569A (ja) 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
US20180000816A1 (en) 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye

Similar Documents

Publication Publication Date Title
JP7169693B2 (ja) 呼吸器疾患の治療
JP6099609B2 (ja) 肺炎症を低減するためのレボフロキサシンの吸入
CN106163557B (zh) 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
JP6424210B2 (ja) プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療
RU2013155903A (ru) Композиции, способы и устройства для респираторной доставки двух или более активных средств
JP2014528474A5 (enExample)
JP2008297311A (ja) 気道疾患の処置のためのプレコナリルを含む薬学的処方物
CN102573823A (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
JP2020536048A5 (enExample)
JP5362151B2 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
KR20120022751A (ko) 스테로이드성［３,２?ｃ］피라졸 유도체 및 제２ 제약 활성 화합물을 포함하는 제약 조성물
Wang et al. N-methyl-D-aspartate receptor activation mediates lung fibroblast proliferation and differentiation in hyperoxia-induced chronic lung disease in newborn rats
UA119774C2 (uk) Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
JP7433331B2 (ja) 特発性肺線維症を治療するための組成物及び方法
TW200402307A (en) Nasal composition
US6262077B1 (en) Composition and method for treating allergic diseases
JP2013518061A5 (enExample)
CA3095859C (en) Bambuterol for the treatment of alzheimer's disease
JP2013542262A5 (enExample)
CN102665705A (zh) 包含非甾体抗炎药和秋水仙碱苷衍生物的活性成分的新组合
CN106535913A (zh) 神经活性肽的稳定组合物
Armstrong et al. The role of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
HK40058742B (en) Treatment of respiratory diseases
Walker American Thoracic Society (ATS) 2014 International Conference-San Diego, California, USA-May 16-21, 2014
CN106659676A (zh) 一种罗哌卡因缓释凝胶制剂及其制备与应用